Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

Full story: BioSpace
Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more) Full Story

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
Fighting Breast Cancer - What You Can Do (Oct '11) Oct 29 Karing1 7
Massive vaccine cover-up confirmed: Secret docu... Oct 28 VACCINE COVERUP 6
Dallas Nurse Who Survived Ebola Must Wait for Dog Oct 25 OccupyThis 1
Dallas Nurse Who Contracted Ebola Now Virus Fre... Oct 24 Speakeasy 1
Dividend Aristocrats In Focus Part 26 of 54: Wa... Oct 23 wag1234 2
Ebola: Keeping patients alive as body fights back Oct 21 BlackJewsandNazer... 1
Ebola monitoring inconsistent as virus spread Oct 20 Elise Gingerich 1

Biotech People Search

Addresses and phone numbers for FREE